secwatch.observer — SEC 8-K summary
======================================

Issuer:     Liquidia Corp (LQDA)
CIK:        0001819576
Form:       8-K
Filed at:   2022-01-04T23:59:59+00:00
Accession:  0001104659-22-000510
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Liquidia appoints Roger Jeffs as CEO; deGoa stays on board through Jan 31
-------------------------------------------------------------------------

- Roger Jeffs, Ph.D., appointed CEO effective Jan 3, 2022; replaces Damian deGoa who remains director through Jan 31.
- Jeffs previously co-CEO/president of United Therapeutics (18 yrs); co-founder/vice chairman of Kriya Therapeutics.
- Employment terms: $650k base salary, 50% annual bonus target, options for 1.68M shares (sign-on) and 0.93M shares (tranche 2).
- DeGoa provided transition support; board chairman cited Jeffs' rare disease and pulmonary hypertension expertise.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819576/000110465922000510/0001104659-22-000510-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819576/000110465922000510/tm221309d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-000510

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer